186 related articles for article (PubMed ID: 15082029)
1. Evidence that the granulocyte colony-stimulating factor (G-CSF) receptor plays a role in the pharmacokinetics of G-CSF and PegG-CSF using a G-CSF-R KO model.
Kotto-Kome AC; Fox SE; Lu W; Yang BB; Christensen RD; Calhoun DA
Pharmacol Res; 2004 Jul; 50(1):55-8. PubMed ID: 15082029
[TBL] [Abstract][Full Text] [Related]
2. Albugranin, a recombinant human granulocyte colony stimulating factor (G-CSF) genetically fused to recombinant human albumin induces prolonged myelopoietic effects in mice and monkeys.
Halpern W; Riccobene TA; Agostini H; Baker K; Stolow D; Gu ML; Hirsch J; Mahoney A; Carrell J; Boyd E; Grzegorzewski KJ
Pharm Res; 2002 Nov; 19(11):1720-9. PubMed ID: 12458679
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of pegfilgrastim.
Zamboni WC
Pharmacotherapy; 2003 Aug; 23(8 Pt 2):9S-14S. PubMed ID: 12921217
[TBL] [Abstract][Full Text] [Related]
4. Prevention of chemotherapy-induced neutropenia with pegfilgrastim: pharmacokinetics and patient outcomes.
Yang BB; Savin MA; Green M
Chemotherapy; 2012; 58(5):387-98. PubMed ID: 23296266
[TBL] [Abstract][Full Text] [Related]
5. Polyethylene glycol modification of filgrastim results in decreased renal clearance of the protein in rats.
Yang BB; Lum PK; Hayashi MM; Roskos LK
J Pharm Sci; 2004 May; 93(5):1367-73. PubMed ID: 15067712
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and pharmacodynamics of pegfilgrastim.
Yang BB; Kido A
Clin Pharmacokinet; 2011 May; 50(5):295-306. PubMed ID: 21456630
[TBL] [Abstract][Full Text] [Related]
7. Pegfilgrastim (PEG-G-CSF) induces anti-PEG IgM in a dose dependent manner and causes the accelerated blood clearance (ABC) phenomenon upon repeated administration in mice.
Elsadek NE; Lila ASA; Emam SE; Shimizu T; Takata H; Ando H; Ishima Y; Ishida T
Eur J Pharm Biopharm; 2020 Jul; 152():56-62. PubMed ID: 32376372
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and Pharmacodynamics of Two Formulations of Pegylated Recombinant Human Granulocyte Colony-Stimulating Factor in Healthy Chinese Subjects: An Open-Label, Randomized, Parallel-Design Bioavailability Study.
Hu C; Ji B; Hu X; Yang C; Sun W; Zhao X; Li L; Li X; Zhang L
Clin Pharmacol Drug Dev; 2021 Mar; 10(3):291-298. PubMed ID: 32567217
[TBL] [Abstract][Full Text] [Related]
9. A pharmacokinetic model of filgrastim and pegfilgrastim application in normal mice and those with cyclophosphamide-induced granulocytopaenia.
Scholz M; Ackermann M; Engel C; Emmrich F; Loeffler M; Kamprad M
Cell Prolif; 2009 Dec; 42(6):813-22. PubMed ID: 19689472
[TBL] [Abstract][Full Text] [Related]
10. The design and development of pegfilgrastim (PEG-rmetHuG-CSF, Neulasta).
Molineux G
Curr Pharm Des; 2004; 10(11):1235-44. PubMed ID: 15078138
[TBL] [Abstract][Full Text] [Related]
11. Pegylated granulocyte colony-stimulating factor conveys long-term neuroprotection and improves functional outcome in a model of Parkinson's disease.
Frank T; Klinker F; Falkenburger BH; Laage R; Lühder F; Göricke B; Schneider A; Neurath H; Desel H; Liebetanz D; Bähr M; Weishaupt JH
Brain; 2012 Jun; 135(Pt 6):1914-25. PubMed ID: 22427327
[TBL] [Abstract][Full Text] [Related]
12. Pegfilgrastim: current and future perspectives in the treatment of chemotherapy-induced neutropenia.
Ricotta R; Cerea G; Schiavetto I; Maugeri MR; Pedrazzoli P; Siena S
Future Oncol; 2006 Dec; 2(6):667-76. PubMed ID: 17155894
[TBL] [Abstract][Full Text] [Related]
13. Retrospective comparison of neutropenia in children with Ewing sarcoma treated with chemotherapy and granulocyte colony-stimulating factor (G-CSF) or pegylated G-CSF.
Milano-Bausset E; Gaudart J; Rome A; Coze C; Gentet JC; Padovani L; Lacarelle B; André N
Clin Ther; 2009; 31 Pt 2():2388-95. PubMed ID: 20110048
[TBL] [Abstract][Full Text] [Related]
14. Transfer of recombinant human granulocyte colony stimulating factor (rhG-CSF) from the maternal to the fetal circulation is not dependent upon a functional G-CSF-receptor.
Calhoun DA; Gersting JA; Lunøe M; Du Y; Christensen RD
Placenta; 2001 Jul; 22(6):609-12. PubMed ID: 11440552
[TBL] [Abstract][Full Text] [Related]
15. Lipegfilgrastim: pharmacodynamics and pharmacokinetics for body-weight-adjusted and 6 mg fixed doses in two randomized studies in healthy volunteers.
Buchner A; Lammerich A; Abdolzade-Bavil A; Müller U; Bias P
Curr Med Res Opin; 2014 Dec; 30(12):2523-33. PubMed ID: 25251999
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic and -dynamic modelling of G-CSF derivatives in humans.
Scholz M; Schirm S; Wetzler M; Engel C; Loeffler M
Theor Biol Med Model; 2012 Jul; 9():32. PubMed ID: 22846180
[TBL] [Abstract][Full Text] [Related]
17. Comparative effectiveness of colony-stimulating factors for febrile neutropenia: a retrospective study.
Tan H; Tomic K; Hurley D; Daniel G; Barron R; Malin J
Curr Med Res Opin; 2011 Jan; 27(1):79-86. PubMed ID: 21091127
[TBL] [Abstract][Full Text] [Related]
18. Design Rationale and Development Approach for Pegfilgrastim as a Long-Acting Granulocyte Colony-Stimulating Factor.
Arvedson T; O'Kelly J; Yang BB
BioDrugs; 2015 Jun; 29(3):185-98. PubMed ID: 25998211
[TBL] [Abstract][Full Text] [Related]
19. Comparison of hospitalization risk and associated costs among patients receiving sargramostim, filgrastim, and pegfilgrastim for chemotherapy-induced neutropenia.
Heaney ML; Toy EL; Vekeman F; Laliberté F; Dority BL; Perlman D; Barghout V; Duh MS
Cancer; 2009 Oct; 115(20):4839-48. PubMed ID: 19637341
[TBL] [Abstract][Full Text] [Related]
20. An assessment of the pharmacokinetics, pharmacodynamics, and tolerability of GCPGC, a novel pegylated granulocyte colony-stimulating factor (G-CSF), in healthy subjects.
Shin KH; Lim KS; Lee H; Jang IJ; Yu KS
Invest New Drugs; 2014 Aug; 32(4):636-43. PubMed ID: 24468886
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
